Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Saved in:
Bibliographic Details
Published inJournal of the American Heart Association Vol. 12; no. 18; p. e029216
Main Authors Goodman, Shaun G., Steg, Philippe Gabriel, Poulouin, Yann, Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Garon, Genevieve, Harrington, Robert A., Jukema, J. Wouter, Manvelian, Garen, Stipek, Wanda, Szarek, Michael, White, Harvey D., Schwartz, Gregory G.
Format Journal Article
LanguageEnglish
Published Hoboken John Wiley and Sons Inc 19.09.2023
Wiley
Subjects
cholesterol
PCSK9
Research Letter
Research Letters
safety
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Undefined-3
Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01663402.
This article was sent to Daniel Edmundowicz, MD, Guest Editor, for review by expert referees, editorial decision, and final disposition.
Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.029216
For Sources of Funding and Disclosures, see page 3.
The ODYSSEY OUTCOMES committee members, investigators, and contributors can be found in the Supplemental Material.
This work was presented in part at the European Society of Cardiology Congress, August 26 to 29, 2022.
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.122.029216